JW Shinyak

JW신약 · 067290

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$55M (₩75.9B)

Overview

JW Shinyak is a South Korean pharmaceutical company that develops and supplies prescription medicines and related health-care products.

Its customers are broadly the hospitals, clinics, and pharmacies that make up the domestic health-care supply chain. The company is listed on KOSDAQ, Korea's tech and small-cap exchange, and operates as a standalone pharmaceutical business following the liquidation of its only consolidated subsidiary.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$58.7M

▼ −12.9% YoY

Operating profit · FY2025

US$5.4M

▼ −25.1% YoY

Net income · FY2025

US$11.3M

▲ +208.4% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$75.5M(₩104.2B)	US$67.4M(₩93B)	US$58.7M(₩81B)
Operating profit	US$4.1M(₩5.6B)	US$7.2M(₩10B)	US$5.4M(₩7.5B)
Net income	−US$27.1M(−₩37.4B)	US$3.7M(₩5.1B)	US$11.3M(₩15.7B)

Revenue

FY2023US$75.5M
FY2024US$67.4M
FY2025US$58.7M

Operating profit

FY2023US$4.1M
FY2024US$7.2M
FY2025US$5.4M

Net income

FY2023−US$27.1M
FY2024US$3.7M
FY2025US$11.3M

Key ratios (FY2025)

ROE

38.4%

Debt/Eq

43.0%

Op. margin

9.2%

Net margin

19.3%

Rev. YoY

▼ −12.9%

Why it matters

The filing notes that JW Shinyak absorbed the former JW Creagen subsidiary, which has since been fully liquidated, leaving the company with no remaining consolidated subsidiaries.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?